(BioNTech) Germany’s BioNTech SE announced €5.3 billion in revenue in the second quarter of 2021, a jump from €41.7 million in the same quarter last year after crossing 1 billion vaccine sales.
The company reported €7.4 billion in the first half-year revenue, an increase from €69.4 million in the same period last year.
BioNTech profit for the second quarter was €2.8 billion, up from a loss position of €88.3 million in the same period last year.
The company’s profit for the first six months of the year was €3.9 billion in contrast to a loss of €141.7 million in the first half of 2020.
BioNTech’s diluted EPS for the second quarter was €10.77, up from a diluted EPS of -0.38 reported in the same quarter last year.
The first half-year diluted EPS was €15.14, up from a loss of €0.62 in the first six months of 2020.
The German biotechnology company announced that its estimated Covid-19 vaccine revenue in the 2021 full-year results will be €15.9 billion, from the current 2.2 billion doses supply contracts.
BNTX: NASDAQ is up +4.83% on pre-market
